Figure 6
IL-13 is necessary for the development of pancreatic fibrosis induced by a low-dose cerulein and NOD1 ligand. C57BL6 mice were administered FK565 followed by a low-dose cerulein for a total of three times as described in Figure 1. Mice were also treated with intraperitoneal injection of control Ab (100 μg, n=4) or anti-IL-13 antibody (100 μg, n=4) before the initiation of FK565-cerulein treatment regimen. Mice received each regimen twice a week for a total of 14 times and then sera and pancreatic tissues were obtained. (a) Serum levels of amylase, pancreatic weight, pathological scores of the pancreas, pancreatic levels of hydroxyproline, and the numbers of α-SMA+ cells obtained from mice 3 h after the last injection of cerulein. Results are expressed as mean±s.e.m.**P<0.01 as compared with control Ab. (b) Concentrations of cytokines and chemokines in pancreatic lysates were determined by ELISA. Levels of cytokines and chemokines in the pancreas are shown as values per 100 mg pancreatic tissue. Results are expressed as mean±s.e.m. *P<0.05 as compared with control Ab. (c) Representative picture of the pancreas tissue stained with H&E, anti-SMA Ab and anti-fibronectin Ab, magnification × 400. Ab, antibody; ELISA, enzyme-linked immunosorbent assay; H&E; hematoxylin and eosin; IL, interleukin; NOD1, nucleotide-binding oligomerization domain 1.
